We are live on ! Find out more
RDY icon

Dr. Reddy's Laboratories

189 hedge funds and large institutions have $1.08B invested in Dr. Reddy's Laboratories in 2023 Q1 according to their latest regulatory filings, with 43 funds opening new positions, 69 increasing their positions, 45 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

207% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 14

53% more repeat investments, than reductions

Existing positions increased: 69 | Existing positions reduced: 45

34% more capital invested

Capital invested by funds: $805M → $1.08B (+$276M)

17% more funds holding

Funds holding: 161189 (+28)

8.44% more ownership

Funds ownership: 49.31%57.75% (+8.4%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

66% less call options, than puts

Call options by funds: $154K | Put options by funds: $450K

Holders
189
Holders Change
+28
Holders Change %
+17.39%
% of All Funds
3.01%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
43
Increased
69
Reduced
45
Closed
14
Calls
$154K
Puts
$450K
Net Calls
-$296K
Net Calls Change
-$338K
Name Holding Trade Value Shares
Change
Change in
Stake
HDIM
126
Hanson & Doremus Investment Management
Vermont
$338K
XT
127
XTX Topco
Cayman Islands
$335K +$317K +29,400 New
Stifel Financial
128
Stifel Financial
Missouri
$314K +$20.1K +1,865 +7%
SW
129
SVB Wealth
Massachusetts
$303K +$61.4K +5,685 +27%
QCM
130
Quantinno Capital Management
New York
$291K -$233K -21,585 -46%
VF
131
Virtu Financial
New York
$283K +$268K +24,855 New
Jane Street
132
Jane Street
New York
$282K -$35.4K -3,280 -12%
SAI
133
Systematic Alpha Investments
New Jersey
$279K
PI
134
Putnam Investments
Massachusetts
$279K +$264K +24,475 New
SSA
135
Schonfeld Strategic Advisors
New York
$273K +$259K +24,000 New
FC
136
FORA Capital
Florida
$262K +$248K +23,005 New
PP
137
PDS Planning
Ohio
$257K +$243K +22,545 New
Squarepoint
138
Squarepoint
New York
$252K -$280K -25,985 -54%
CIM
139
Confluence Investment Management
Missouri
$244K
First Trust Advisors
140
First Trust Advisors
Illinois
$243K -$3.02M -279,485 -93%
PA
141
Parallel Advisors
California
$240K +$61.7K +5,720 +37%
Aviva
142
Aviva
United Kingdom
$239K -$3.94K -365 -2%
DCM
143
Deuterium Capital Management
Florida
$230K +$218K +20,180 New
CGH
144
Crossmark Global Holdings
Texas
$229K +$217K +20,125 New
TRCT
145
Tower Research Capital (TRC)
New York
$223K +$192K +17,745 +929%
JIC
146
Johnson Investment Counsel
Ohio
$216K +$205K +18,960 New
National Bank of Canada
147
National Bank of Canada
Quebec, Canada
$214K +$201K +18,625 New
MYIA
148
Mount Yale Investment Advisors
Colorado
$208K +$197K +18,230 New
SIA
149
Schechter Investment Advisors
Michigan
$202K -$37.8K -3,505 -17%
Russell Investments Group
150
Russell Investments Group
United Kingdom
$195K

RDY Hedge Fund Activity: Q1 2023 in Review

189 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Dr. Reddy's Laboratories (RDY) for Q1 2023, worth a combined $1.08B — up 34% from $805M a quarter earlier.

Buyers outnumbered sellers: 43 funds opened new RDY positions and 14 closed out — a net gain of 29 holders — while 69 added to existing stakes and 45 trimmed.

The largest buyer was Bank of America, adding an estimated $25.3M. The largest seller was Connor, Clark & Lunn Investment Management (CC&L), cutting an estimated $5.12M.

  • 189 institutional investors held Dr. Reddy's Laboratories (RDY) as of Q1 2023, up from 161 in Q4 2022.
  • Funds reported $1.08B of Dr. Reddy's Laboratories stock for Q1 2023, up 34% quarter-over-quarter.
  • 43 funds opened new Dr. Reddy's Laboratories positions in Q1 2023 and 14 closed out, a net change of +29 holders.
  • The largest Dr. Reddy's Laboratories buyer in Q1 2023 was Bank of America, an estimated $25.3M added.
  • The largest Dr. Reddy's Laboratories seller in Q1 2023 was Connor, Clark & Lunn Investment Management (CC&L), an estimated $5.12M sold.

Based on aggregated 13F filings for Q1 2023.